Sijin Park, PA
Physician Assistant · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 3
Offices
3 locations · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Alta Bates Summit Medical Center - Alta Bates Camp. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Sijin Park’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence G55658 · Cancelled
Licence status: Cancelled · since 1985 · University of Hawaii School of Medicine.
License has been voluntarily canceled, or the license has been expired for at least five years and has not been renewed. No practice is permitted.
Matched on the licence number without its letter prefix; check the name before relying on it.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Alta Bates Summit Medical Center - Alta Bates CampBerkeley, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.298, Oct 2024 – Sep 2025
See every measure and the patient survey for Alta Bates Summit Medical Center - Alta Bates Camp
Behind the star rating — Deaths: 2 better, 5 the same, 0 worse of 7 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 6 the same, 1 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.298 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.18 (0.16 to 2.2) · 730 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.87 (0.51 to 1.23) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 188.12 (132.31 to 243.94) · 50 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 6.8 · 50 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.4 · 189 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.6 · 184 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 103 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 1,585 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.4) · 3,929 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.31 (0.11 to 0.51) · 3,954 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.15 (0.95 to 5.36) · 754 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.62 (0 to 3.33) · 325 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.99 (0.39 to 3.59) · 717 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.85 (2.27 to 19.44) · 326 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.79 (1.08 to 8.49) · 302 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.68 (0.19 to 3.18) · 184 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.17 (0 to 0.88) · 3,240 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.4 · 161 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.207 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.48 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.785 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.4 · 243 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -58.2 · 194 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -12.3 · 177 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 209 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.4 (3.8 to 7.5) · 215 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.2 (9.4 to 15.5) · 215 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.8 · 150 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.2 · 81 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.4 (10 to 18.1) · 315 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1.2) · 137 cases | No different | Jan 2024 – Dec 2024 |
What patients said (449 patients answered, 15% of those asked)
| Cleanliness | 2 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 2 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 62% |
| Nurses "always" communicated well | 72% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 53% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 68% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 58% |
| Staff "always" explained new medications | 67% |
| Nurses "always" explained things so they could understand | 67% |
| Nurses "always" listened carefully | 66% |
| Nurses "always" treated them with courtesy and respect | 81% |
| "Always" quiet at night | 49% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 38% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
Original Medicare doctor bills
$91,392
Medicare paid this office $91,392 for 326 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Hyaluronan or derivative, durolane, for intra-articular injection, 1 mg | 49 | $21,747 | None |
| New patient visit (45+ min) | 174 | $19,786 | $114 |
| Short return visit (20+ min) | 156 | $15,798 | $72 |
| Aspiration and/or injection of fluid from large joint | 119 | $10,784 | $59 |
| Hyaluronan or derivative, orthovisc, for intra-articular injection, per dose | 33 | $10,556 | None |
See all 10 services
| Hyaluronan or derivative, durolane, for intra-articular injection, 1 mg | 49 | $21,747 | None |
| New patient visit (45+ min) | 174 | $19,786 | $114 |
| Short return visit (20+ min) | 156 | $15,798 | $72 |
| Aspiration and/or injection of fluid from large joint | 119 | $10,784 | $59 |
| Hyaluronan or derivative, orthovisc, for intra-articular injection, per dose | 33 | $10,556 | None |
| Return visit (30+ min) | 78 | $8,898 | $99 |
| New patient visit (30+ min) | 20 | $1,711 | $86 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 44 | $199 | None |
| Injection, methylprednisolone acetate, 1 mg | 14 | $79 | None |
| Injection, methylprednisolone acetate, 40 mg | 12 | $71 | None |
Who their Medicare patients are
326 Original Medicare patients in 2024. Average age 75 · Women 62% · Also on Medicaid 12% · Health risk score 0.97. At or below the middle of the specialty; the typical physician assistant clinician is at 1.31.
Conditions among them: High blood pressure 57% · Chronic kidney disease 20% · Diabetes 19% · Coronary heart disease 18% · Cancer 14% · Atrial fibrillation 14% · Depression 13% · Heart failure 8% · COPD 7% · Stroke 6%.
The office billed $925,881, Medicare allowed $121,258 and paid $91,392; for 6,146 services of 25 kinds; $32,957 of it was for drugs given in the office and $58,435 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 326 | 6,146 | 75 | 0.97 | $925,881 | $91,392 |
| 2023 | 162 | 1,341 | 74 | 0.97 | $347,048 | $34,904 |
| 2022 | 83 | 99 | 74 | 1.07 | $19,948 | $5,162 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 6 services
| Short return visit (20+ min) | 103 | $8,567 | $64 |
| Hyaluronan or derivative, orthovisc, for intra-articular injection, per dose | 29 | $8,368 | None |
| Aspiration and/or injection of fluid from large joint | 51 | $5,168 | $62 |
| New patient visit (30+ min) | 45 | $3,825 | $85 |
| Return visit (30+ min) | 13 | $1,157 | $89 |
| Injection, methylprednisolone acetate, 40 mg | 25 | $208 | None |
2022: 2 services
| Short return visit (20+ min) | 67 | $3,916 | $50 |
| New patient visit (30+ min) | 13 | $769 | $59 |
Medicaid work
$337 in 2019
Medicaid paid $337 for 280 billed services this clinician did in 2019, up to 48 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Short return visit (20+ min) | 191 | $262 |
| Return visit (30+ min) | 61 | $75 |
| HEMOGLOBIN | 28 | $0 |
| 2019 | 280 | 3 | 48 | $337 |
Drugs they prescribed that Part D paid
$3,525
Pharmacies billed $3,525 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 16% of their Part D prescriptions (42 of 261) in 2024. Above the middle of the specialty; the typical physician assistant clinician is at 1%.
261 generic and 0 brand-name prescriptions · $3,525 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Celecoxib | 32 | $938 | $29 |
| Gabapentin | 58 | $860 | $15 |
| Diclofenac | 32 | $468 | $15 |
| Meloxicam | 35 | $168 | $5 |
| Ondansetron | 28 | $156 | $6 |
See all 6 drugs
| Celecoxib | 32 | $938 | $29 |
| Gabapentin | 58 | $860 | $15 |
| Diclofenac | 32 | $468 | $15 |
| Meloxicam | 35 | $168 | $5 |
| Ondansetron | 28 | $156 | $6 |
| Oxycodone | 28 | $156 | $6 |
Year by year
| 2024 | 261 | 124 | 16% (42) | 0% | $3,525 |
| 2023 | 308 | 159 | 40% (123) | None | $6,280 |
| 2022 | 607 | 137 | 5% (30) | 6% | $35,953 |
| 2021 | 607 | 111 | 0% (0) | 9% | $31,775 |
| 2020 | 334 | 66 | 0% (0) | 10% | $13,686 |
| 2019 | 177 | 45 | 0% (0) | None | $2,731 |
| 2018 | 59 | 19 | 0% (0) | None | $832 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 5 drugs
| Celecoxib | 34 | $1,978 | $58 |
| Oxycodone | 92 | $670 | $7 |
| Gabapentin | 47 | $617 | $13 |
| Diclofenac | 17 | $423 | $25 |
| Ondansetron | 19 | $119 | $6 |
2022: 12 drugs
| Celecoxib | 16 | $1,288 | $80 |
| Atorvastatin | 63 | $571 | $9 |
| Gabapentin | 38 | $429 | $11 |
| Metformin | 55 | $412 | $7 |
| Losartan | 31 | $273 | $9 |
| Levothyroxine | 17 | $197 | $12 |
| Oxycodone | 19 | $187 | $10 |
| Lisinopril | 38 | $183 | $5 |
| Hydrochlorothiazide | 34 | $151 | $4 |
| Tamsulosin | 18 | $130 | $7 |
| Amlodipine Besylate | 27 | $121 | $4 |
| Glipizide | 19 | $114 | $6 |
2021: 11 drugs
| Atorvastatin | 66 | $855 | $13 |
| Losartan | 45 | $468 | $10 |
| Amlodipine Besylate | 44 | $405 | $9 |
| Metformin | 54 | $387 | $7 |
| Levothyroxine | 13 | $253 | $19 |
| Lisinopril | 36 | $249 | $7 |
| Omeprazole | 18 | $157 | $9 |
| Glipizide | 25 | $122 | $5 |
| Hydrochlorothiazide | 26 | $106 | $4 |
| Atenolol | 19 | $74 | $4 |
| Simvastatin | 12 | $69 | $6 |
2020: 7 drugs
| Atorvastatin | 36 | $434 | $12 |
| Losartan | 24 | $284 | $12 |
| Amlodipine Besylate | 38 | $272 | $7 |
| Fluticasone Propionate | 11 | $212 | $19 |
| Lisinopril | 27 | $173 | $6 |
| Metformin | 21 | $163 | $8 |
| Glipizide | 14 | $63 | $5 |
2019: 4 drugs
| Levothyroxine | 12 | $229 | $19 |
| Atorvastatin | 22 | $225 | $10 |
| Metformin | 16 | $66 | $4 |
| Lisinopril | 12 | $58 | $5 |
Money from drug and device companies
$17 in 2025
| 2025 | 1 | 1 | None | $17 |
| 2024 | 1 | 1 | None | $35 |
| 2023 | 2 | 2 | None | $129 |
| 2022 | 2 | 2 | None | $215 |
| 2021 | 2 | 5 | None | $187 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Pacira Pharmaceuticals | Exparel | $17 | 1 payment
|
See the published payment
| Pacira Pharmaceuticals | Meals · 2025-02-19 | Exparel | $17 |
See earlier years (2024, 2023, 2022, 2021)
2024: $35
| Evolution Surgical | None | $35 | 1 payment
|
2023: $129
| Medical Device Business Services | None | $98 | 1 payment
|
| Evolution Surgical | None | $31 | 1 payment
|
2022: $215
| Amgen | Prolia | $113 | 1 payment
|
| Galderma Laboratories L.P. | None | $102 | 1 payment
|
2021: $187
| Novo Nordisk | Rybelsus | $175 | 4 payments
|
| Dynavax Technologies | Heplisav-B | $12 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1588157879
- Licence
- CA 55658California G55658: Cancelled
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Physician assistant (363A00000X); Physician assistant, surgical (363AS0400X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2018-06-11
- NPI last updated
- 2025-12-23
- NPI record certified
- 2025-12-23
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 2880 Story Rd # 10, San Jose, CA, 95127